The aim of this study was to investigate the effects of a non-standard, intermittent imatinib treatment in elderly patients with Philadelphia-positive chronic myeloid leukaemia and to answer the question on which dose should be used once a stable optimal response has been achieved. Seventy-six patients aged ⩾65 years in optimal and stable response with ⩾2 years of standard imatinib treatment were enrolled in a study testing a regimen of intermittent imatinib (INTERIM; 1-month on and 1-month off). With a minimum follow-up of 6 years, 16/76 patients (21%) have lost complete cytogenetic response (CCyR) and major molecular response (MMR), and 16 patients (21%) have lost MMR only. All these patients were given imatinib again, the same dose, on the standard schedule and achieved again CCyR and MMR or an even deeper molecular response. The probability of remaining on INTERIM at 6 years was 48% (95% confidence interval 35-59%). Nine patients died in remission. No progressions were recorded. Side effects of continuous treatment were reduced by 50%. In optimal and stable responders, a policy of intermittent imatinib treatment is feasible, is successful in about 50% of patients and is safe, as all the patients who relapsed could be brought back to optimal response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648524 | PMC |
| http://dx.doi.org/10.1038/bcj.2015.75 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Jejunojejunal intussusception induced by a gastrointestinal stromal tumor: a case report and literature review.
J Int Med Res
April 2024
Department of Surgery, University of Calabar/University of Calabar Teaching Hospital, Calabar, Nigeria.
Intussusception is defined as the invagination of a proximal segment of the bowel into the adjoining or distal segment. In most adults with intussusception, there is a demonstrable lead point with a definite pathologic abnormality. The clinical features of intussusception include chronic intermittent abdominal pain, nausea and vomiting, constipation, and a palpable abdominal mass.
View Article and Find Full Text PDFTwenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient.
Ther Adv Hematol
December 2023
Unit of Blood Diseases and Cell Therapies, Department of Clinical and Experimental Sciences, ASST-Spedali Civili Hospital of Brescia, University of Brescia, Brescia, Italy.
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for CML therapy and has revolutionized the life expectancy of CML patients, which is now quite like the one of the healthy aged population. Over the last 20 years, both the TKI therapy itself and the objectives have undergone evolutions highlighted and discussed in this review. The main objective of the CML therapy in the first 10 years after TKI introduction was to abolish the disease progression from the chronic to the blastic phase and guarantee the long-term survival of the great majority of patients.
View Article and Find Full Text PDFCase report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia.
Front Pharmacol
November 2023
Department of Hematology and Oncology, Jiujiang University Affiliated Hospital, Jiujiang, Jiangxi, China.
The advent of first- and second-generation BCR/ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, has markedly improved the clinical outcomes of patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). However, due to acquired drug resistance, most Ph-ALL patients experience relapse. Thus, third-generation BCR/ABL1 TKIs, including ponatinib and olverembatinib, have been developed with the aim of overcoming drug resistance.
View Article and Find Full Text PDFRecurrent malignant solitary fibrous tumor of pelvis: A case report and treatment approach.
Medicine (Baltimore)
August 2023
Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- Solitary fibrous tumors (SFTs) are unusual growths primarily found in the pleura but can appear in other areas, including bones; a case of a malignant SFT in the pelvis has not been previously documented.* -
- A 15-year-old male presented with numbness and pain in his lower limbs, leading to the discovery of a significant tumor near the sacrum, which was surgically removed.* -
- After surgery, the tumor returned within nine months, and treatment with imatinib showed promising results, highlighting the need for further studies on the management of recurrent malignant SFTs.*
Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
Ann Hematol
August 2023
Department of Medical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi, India.
Chronic myeloid leukemia (CML) management during pregnancy is challenging. In this retrospective study, hospital records of CML patients treated between 2000 and 2021 were screened to identify patients who tried to conceive/got pregnant (planned and unplanned) on TKIs (tyrosine kinase inhibitors)/were pregnant at CML onset/fathered a child. We found ninety-three pregnancies involving thirty-three women and thirty-eight men, and they were analyzed for the pregnancy outcomes and the strategies utilized for CML management during pregnancy and the pre-conception period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!